OBSV News and Press, ObsEva SA From 04/29/19

Geneva, Switzerland and Boston, MA – April 29 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive h...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. China's Vice Premier Liu plans to travel to the U.S. next week in what could be ano...

Geneva, Switzerland and Boston, MA – March 29, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive hea...

Geneva, Switzerland and Boston – March 13, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health ...

ObsEva SA (OBSV) Q4 2018 Earnings Conference Call March 05, 2019 08:00 AM ET Company Participants Mario Corso - Senior Director, Investor Relations Ernest Loumaye - Co-founder and Chief Executive Officer Tim Adams - Chief Financial Officer Wim Souverijns - Chief Commercial Offi...

ObsEva (NASDAQ: OBSV ): Q4 GAAP EPS of -$0.46 beats by $0.02 . More news on: ObsEva, Earnings news and commentary, Healthcare stocks news, Read more ...

Major 2018 Accomplishments Driven by Positive Clinical Trial Results - Significant increase in rates of pregnancy and live birth (up to 35% increase in Day 5 ET) in Phase 3 IMPLANT 2 trial of nolasiban in IVF procedures -Significant reduction in pain symptoms (3/4 of p...

Geneva, Switzerland and Boston, MA –February 27, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproduc...

Geneva, Switzerland and Boston, MA – February 22, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive ...